Comparison of simple and complex liver intensity modulated radiotherapy

An effective and optimized patient-specific QA workload reduction for VMAT plans after MLC-modelling optimization

INTRODUCTION

Many complexity metrics characterize modulated plans. First, this study aimed at identify the optimal complexity metrics to reduce workload associated to patient-specific quality assurance (PSQA) for our equipment and processes. Second, it intended to optimize our MLC modelling to improve measurement and calculation agreement with expectation of further reducing PSQA workload.

METHODS

Correlation and sensitivity at specificity equals to 1 were evaluated for PSQA results and different complexity metrics. Thresholds to stop PSQA were determined. After validation of the optimal complexity metric and threshold for our equipment and process, the MLC modelling was reviewed with a recently published methodology. This method is based on measurements with a Farmer-type ionization chamber of synchronous and asynchronous sweeping gap plans. Effect on the PSQA results and the identified threshold was investigated.

RESULTS

In our center, the most appropriate complexity metric for reducing our PSQA workload was the Modulation Complexity Score for VMAT (MCSv). The optimization of the MLC modelling significantly reduced the number of controlled plans, specifically for one of our two Varian Clinac. Any plan with a MCSv >= 0.34 is treated without PSQA.

CONCLUSION

This study rationalized and reduced our PSQA workload by approximately 30%. It is a continuing work with new TPS, machine or PSQA equipment. It encourages centers to re-evaluate their MLC modelling as well as assess the benefit of complexity metrics to streamline their PSQA workflow. An easier access, at least for reporting, at best for optimizing plans, into the TPS would be beneficial for the community.

A measurement validation of improved plan deliverability with monitor unit objective tool for spine stereotactic ablative radiotherapy

Spine stereotactic body radiation therapy (SBRT) uses high dose per fraction for palliative pain control. The treatment plans are often heavily modulated due to close proximity to spinal cord and this can lead to poor plan quality which are susceptible to dose delivery discrepancy. Therefore, we aim to assess the effectiveness of the monitor unit (MU) objective tool in Eclipse treatment planning systems in modulating the plan complexity to improve the plan quality in spine SBRT. Seven retrospective spine SBRT plans are re-optimized using the MU objective tool in Eclipse TPS v13.6 and were compared with the original plans. The dose metrics of the tumor PTV were compared using D_1cc. D_99%, D_95%, D_0.03cc, D_0.1cc, D_0.35cc and D_1cc, and that of cord PRV were compared using D_0.03cc, D_0.1cc, D_0.35cc. Four different plan complexities were also calculated for the original and re-optimized plans to quantify the impact of the tool on the modulation. Patient specific quality assurance measurements were performed with Stereophan and SRS MapCheck, and analyzed using the 1%/1-mm and 2%/2-mm criteria with gamma analysis. The dose metrics of the PTV and cord PRV of the re-optimized and original plans are similar and still meet the planning dose constraints. In particular, the PTV dose coverage has a small percentage difference of (0.15 ± 1.33)% and (0.01 ± 1.04)% for D_99% and D_95%, respectively. The 4 calculated plan complexity metrics consistently show that the re-optimized plans are quantitatively less complex than the original plan. The gamma passing rate of the re-optimized plans improved from (92.2 ± 2.0)% to (94.2 ± 1.6)% with the 1%/1-mm criterion, and (98.7 ± 1.0)% to (99.5 ± 0.3)% with the 2%/2-mm criterion. Overall, the re-optimized plans achieve at least a 10% MU reduction (11.7% to 24.6%). Our study shows that optimization with the MU objective tool can reduce plan complexity and improves dose delivery accuracy, while not compromising the dose distribution.

Evaluation of treatment plan quality for head and neck IMRT: a multicenter study

Intensity-modulated radiotherapy (IMRT) treatment planning for head and neck cancer is challenging and complex due to many organs at risk (OAR) in this region. The experience and skills of planners may result in substantial variability of treatment plan quality. This study assessed the performance of IMRT planning in Malaysia and observed plan quality variation among participating centers. The computed tomography dataset containing contoured target volumes and OAR was provided to participating centers. This is to control variations in contouring the target volumes and OARs by oncologists. The planner at each center was instructed to complete the treatment plan based on clinical practice with a given prescription, and the plan was analyzed against the planning goals provided. The quality of completed treatment plans was analyzed using the plan quality index (PQI), in which a score of 0 indicated that all dose objectives and constraints were achieved. A total of 23 plans were received from all participating centers comprising 14 VMAT, 7 IMRT, and 2 tomotherapy plans. The PQI indexes of these plans ranged from 0 to 0.65, indicating a wide variation of plan quality nationwide. Results also reported 5 out of 21 plans achieved all dose objectives and constraints showing more professional training is needed for planners in Malaysia. Understanding of treatment planning system and computational physics could also help in improving the quality of treatment plans for IMRT delivery.

What is plan quality in radiotherapy? The importance of evaluating dose metrics, complexity, and robustness of treatment plans

Plan evaluation is a key step in the radiotherapy treatment workflow. Central to this step is the assessment of treatment plan quality. Hence, it is important to agree on what we mean by plan quality and to be fully aware of which parameters it depends on. We understand plan quality in radiotherapy as the clinical suitability of the delivered dose distribution that can be realistically expected from a treatment plan. Plan quality is commonly assessed by evaluating the dose distribution calculated by the treatment planning system (TPS). Evaluating the 3D dose distribution is not easy, however; it is hard to fully evaluate its spatial characteristics and we still lack the knowledge for personalising the prediction of the clinical outcome based on individual patient characteristics. This advocates for standardisation and systematic collection of clinical data and outcomes after radiotherapy. Additionally, the calculated dose distribution is not exactly the dose delivered to the patient due to uncertainties in the dose calculation and the treatment delivery, including variations in the patient set-up and anatomy. Consequently, plan quality also depends on the robustness and complexity of the treatment plan. We believe that future work and consensus on the best metrics for quality indices are required. Better tools are needed in TPSs for the evaluation of dose distributions, for the robust evaluation and optimisation of treatment plans, and for controlling and reporting plan complexity. Implementation of such tools and a better understanding of these concepts will facilitate the handling of these characteristics in clinical practice and be helpful to increase the overall quality of treatment plans in radiotherapy.

Complexity metrics for IMRT and VMAT plans: a review of current literature and applications

Modulated radiotherapy with multileaf collimators is widely used to improve target conformity and normal tissue sparing. This introduced an additional degree of complexity, studied by multiple teams through different properties. Three categories of complexity metrics were considered in this review: fluence, deliverability and accuracy metrics. The first part of this review is dedicated to the inventory of these complexity metrics. Different applications of these metrics emerged. Influencing the optimizer by integrating complexity metrics into the cost function has been little explored and requires more investigations. In modern treatment planning system, it remains confined to MUs or treatment time limitation. A large majority of studies calculated metrics only for analysis, without plan modification. The main application was to streamline the patient specific quality assurance workload, investigating the capability of complexity metrics to predict patient specific quality assurance results. Additionally complexity metrics were used to analyze behaviour of TPS optimizer, compare TPS, operators and plan properties, and perform multicentre audit. Their potential was also explored in the context of adaptive radiotherapy and automation planning. The second part of the review gives an overview of these studies based on the complexity metrics.

Relationship of segment area and monitor unit efficiency in aperture-based IMRT optimization

In step‐and‐shoot IMRT plans, aperture‐based optimization (or one‐step optimization) has been considered as a means of improving monitor unit (MU) efficiency compared to fluence‐based optimization (or two‐step optimization). However, the extent of improvement on MU efficiency varies, depending on the implementation and design of one‐step optimization. In this paper, we attempted to investigate MU efficiency issue in two methods of one‐step optimization implemented in two commercial treatment planning systems (TPSs). Five patients with nasopharyngeal cancer and five patients with advanced prostate cancer were selected for this study. For these patients, clinically used IMRT plans were generated using the Direct Machine Parameter Optimization (DMPO) in the Pinnacle TPS. New IMRT plans were created using the Direct Aperture Optimization (DAO) method in the Panther TPS. For the purpose of this study, we used the similar planning dose objectives and beam configurations with a similar total number of segments in each pair of DMPO and DAO plans. With similar plan quality, DMPO plans required more MUs than DAO plans. The average number of MUs (expressed in mean ±1 SD) for the DMPO and DAO plans was 1,169±186 and 671±135 for the nasopharynx cases, and 711±48 and 400±65 for the prostate cases, respectively. The average segment areas (expressed in mean ±1 SD) for the DMPO plans were smaller than those for the DAO plans: 46.0±7.6 cm2 vs. 100.9±32.3 cm2 for the nasopharynx cases, and 58.3±17.2 cm2 vs. 97.4±35.0 cm2 for the prostate cases, respectively. In conclusion, two one‐step optimization algorithms, DMPO and DAO, resulted in much different MU efficiency with the similar number of segments and optimization parameters. This MU difference is largely attributed to the fact that large area segments are used more often in DAO plans than in DMPO plans.

PACS number: 87.55.de

Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments

PURPOSE

The aim of this article is to report the dosimetric and clinical findings in the treatment of primary hepatocellular carcinoma (HCC) with volumetric modulated arc therapy (VMAT, RapidArc).

METHODS AND MATERIALS

A total of 138 patients were investigated. Dose prescription ranged from 45-66 Gy. Most patients (88.4 %) presented AJCC stage III or IV and 83 % were N0-M0. All were classified as Barcelona Clinic Liver Cancer (BCLC) stage A-C. All patients were treated using 10 MV photons with single or multiple, coplanar or non-coplanar arcs, and cone-down technique in case of early response of tumors.

RESULTS

The patients' median age was 66 years (range 27-87 years), 83 % were treated with 60 Gy (12 % at 45 Gy, 6 % at 66 Gy), 62 % with cone-down, 98 % with multiple arcs. The mean initial planning target volume (PTV) was 777 ± 632 cm(3); the mean final PTV (after the cone-down) was 583 ± 548 cm(3). High target coverage was achieved. The final PTV was V98% > 98 %. Kidneys received on average 5 and 8 Gy (left and right), while the maximum dose to the spinal cord was 22 Gy; mean doses to esophagus and stomach were 23 Gy and 15 Gy, respectively. The average volume of healthy liver receiving more than 30 Gy was 294 ± 145 cm(3). Overall survival at 12 months was 45 %; median survival was 10.3 months (95 % confidence interval 7.2-13.3 months). Actuarial local control at 6 months was 95 % and 93.7 % at 12 months. The median follow-up was 9 months and a maximum of 28 months.

CONCLUSION

This study showed from the dosimetric point of view the feasibility and technical appropriateness of RapidArc for the treatment of HCC. Clinical results were positive and might suggest, with appropriate care, to consider RapidArc as an additional therapeutic opportunity for these patients.